Skip to main content
SpringerLink
Log in

Real-world rates and costs of EGFR-TKI-related adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Subramanian J, et al. Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs. 19th World Conference on Lung Cancer : abstr. P2.15-26, 23 Sep 2018.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Real-world rates and costs of EGFR-TKI-related adverse events. Reactions Weekly 1724, 9 (2018). https://doi.org/10.1007/s40278-018-52988-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-52988-6

Search

Navigation